Healthcare has no shortage of promising AI.
The harder part begins after the pilot: deciding which use cases deserve to scale, fitting the technology into clinical workflow, establishing governance and safety, integrating with the systems around it, getting clinicians to use it, and proving that the programme is creating value rather than simply producing activity.
I advise healthcare leaders through that transition.
Not AI strategy as a list of use cases. Not another innovation roadmap built around what the technology might eventually do.
The work is deciding what is worth deploying, what the organisation is actually ready for, and what has to be true for AI to work in production.
AI pilots often begin in the easiest possible conditions: a motivated clinical champion, a defined dataset, vendor support close at hand and a narrow group of users.
Enterprise deployment removes those protections.
Now the technology has to work across different clinicians, shifts, specialties, sites, devices and levels of enthusiasm. Governance has to hold. Exceptions need owners. Integration has to be reliable. Someone has to measure whether the original problem is actually improving.
That is usually where the real programme starts.
The strongest AI use case is not necessarily the one with the most impressive technology.
It is the one where there is a meaningful clinical or operational problem, sufficient data, a workflow where the output can change an action, an accountable owner and a measurable definition of value.
If those pieces are missing, accuracy alone will not rescue the programme.
AI that creates another screen, another inbox or another place for a clinician to look is not automatically helping.
The useful question is where the output needs to appear, who needs to see it, what they should do with it, and how that action fits into the workflow they already use.
Clinical AI succeeds or fails at that point.
Governance cannot live only in the approval committee.
Who owns model performance after go-live? What is monitored? When is a result overridden? How are incidents handled? What happens when the clinical environment changes? How is vendor performance challenged?
Governance has to survive production, not just approve it.
Assess the current pipeline of AI opportunities against clinical value, operational value, data readiness, integration complexity, change burden and realistic ability to scale.
The objective is to stop treating every interesting use case as an equal programme.
Outcome: A prioritised AI portfolio with a clear reason for what goes first, what waits and what should not be pursued.
Assess whether the organisation has the data, governance, architecture, clinical ownership, integration capability and change capacity needed for the programme being proposed.
This is often more useful before procurement than after the first pilot stalls.
Outcome: The gaps that have to be resolved before scale becomes realistic.
Challenge the proposition beyond model performance.
How does it fit the workflow? What does the integration actually require? What data leaves the organisation? What does the vendor monitor? What happens when the model changes? What evidence supports the claimed benefit? Who owns the operational work around it?
A technically capable product can still be the wrong deployment.
Define the operating controls around the technology: accountability, clinical oversight, human review, escalation, monitoring, exception management and the point at which the organisation should intervene.
The objective is not governance for its own sake. It is enough control to make deployment safe without making it impossible.
Turn a successful pilot into an enterprise deployment plan.
That includes workflow integration, system dependencies, adoption, support model, governance, rollout sequencing, measurement and the organisational decisions that cannot remain unresolved at scale.
Outcome: A path to production that goes beyond "expand to more users."
Usage is not the outcome.
Measure whether clinicians continue to use the capability, whether it changes the intended workflow, whether time or cost has actually moved, whether quality has improved, and whether the value still exists once the programme is operating at scale.
Enterprise ambient AI deployed across 200+ physicians in a multi-site health system.
The work was not simply choosing the technology. Adoption, workflow integration and scaling had to operate across real clinical practice rather than a controlled pilot.
Diagnostic AI deployed into radiology workflows contributed to a 40% reduction in turnaround time.
Again, the model was only part of the result. The operating workflow around it determined whether the output became useful.
That is the perspective behind this practice: not whether healthcare AI can work, but what the organisation has to do for it to keep working after go-live.
The technical output is only one part of the deployment.
The programme has to address clinician trust, documentation workflow, specialty variation, EHR integration, quality review, adoption and what happens when generated content is wrong.
Radiology and diagnostic AI live inside time-critical clinical processes.
Worklist integration, prioritisation, clinical review, false-positive handling, escalation and measurement of actual turnaround or diagnostic value matter as much as model capability.
An alert that is accurate but ignored has little value.
Decision support has to enter the workflow at the right point, with enough context to change an action without becoming another source of alert fatigue.
Some of the highest-value use cases are not diagnostic at all.
Scheduling, patient access, documentation, revenue cycle, workflow orchestration and operational decision support can create measurable value where the problem and the action are clearly defined.
The question remains the same: what changes because the AI is there?
It has to coexist with the EMR, identity, integration architecture, digital platforms, data environment, security controls and clinical governance already in place.
That is why I approach AI as part of healthcare technology strategy rather than as a separate innovation discipline.
The model may be new.
The operating environment it has to survive usually is not.
For organisations where FHIR, HL7, APIs or EHR integration are the constraint, the interoperability advisory practice goes deeper into that architecture.
FHIR & Healthcare Interoperability Advisory
There is no preferred model, platform or vendor attached to the advice.
I can help define the use case, challenge the vendor, assess readiness, design the operating model, structure governance and guide the route from pilot to production.
Your technology teams and vendors implement the underlying products. I remain on the organisation's side of the decision.
That independence matters in a market where almost everyone explaining why an AI product should be deployed is also selling one.
Whether you are setting an AI strategy, deciding which use cases to fund, evaluating a vendor, trying to scale a successful pilot or working through a programme that has stalled between innovation and operations, let's have a conversation.
Thank you. Your message has been sent.
You will hear back directly, usually within a couple of days.
Prefer email? rajiv.ganapathy@nirvaanadvisory.com